Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17377078.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Changes in the Jehovah's Witness (JW) blood refusal policy now give members the personal choice to accept certain processed fractions of blood, such as factor concentrates and cryoprecipitate. Two JW patients undergoing complex aortic surgery who developed severe microvascular bleeding after prolonged use of cardiopulmonary bypass were treated with recombinant activated factor VII, cryoprecipitate, and antithrombin concentrate. Cardiopulmonary bypass-induced coagulopathy was successfully treated, allowing chest closure without evidence of thrombotic complications. Processed blood fractions can be a valuable adjuvant to drugs when treating bleeding in JW patients.
Medical subject headings
- Blood Loss, Surgical
- Cardiopulmonary Bypass
- Coagulants
- Factor VIIa
- Jehovah's Witnesses
- Patient Acceptance of Health Care
- Religion and Medicine